Introduction
Chronic myeloid leukemia (CML) is caused by BCR-ABL, a constitutively active tyrosine kinase that results from the t(9;22)(q34;q11), karyotypically evident as the Philadelphia chromosome (Ph).
1 CML cells are characterized by increased proliferation, reduced apoptosis and a perturbation of their interaction with the bone marrow stroma. 2, 3 BCR-ABL activates multiple signaling pathways, including MAPK, JNK, STAT5, PI3K
and SRC, but the precise contribution of the various activated pathways to the biologic features of CML cells and the key molecules that mediate them are not well defined. [4] [5] [6] [7] [8] In contrast to their normal counterparts, CML CD34+ cells are capable of entering into the S phase in the absence of cytokines, consistent with impaired cell cycle control. 9 There is evidence that BCR-ABL exerts its cell cycle effects by altering the function of p27, a key regulator of cell cycle progression. [10] [11] [12] [13] Thus in cell lines, BCR-ABL kinase activity is correlated with increased expression of SKP2, the F-box protein of the E3 ligase SCF SKP2 , which promotes ubiquitination and proteasomal degradation of p27. 14 This phenomenon is not restricted to CML as advanced solid tumors also exhibit a high rate of p27 degradation concomitant with high SKP2 levels are correlated. [15] [16] [17] [18] The fact that SKP2 and activated RAS cooperate in vitro in fibroblast transformation assays has led to the notion that SKP2 is an oncogene. 19, 20 However, the role of SKP2 as a tumor promoter has not been validated in vivo. Here we show that induction of a murine myeloproliferative disease (MPD) by BCR-ABL is partially dependent on SKP2. Our data implicate SKP2 as a crucial downstream mediator of BCR-ABL transformation in vivo and provide in vivo evidence that SKP2 promotes leukemogenesis.
only.
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Materials and methods

Cell lines
The Mo7ep210 BCR-ABL , Ba/F3p210 BCR-ABL and 32Dp210 BCR-ABL cell lines were maintained in RPMI1640 media supplemented with 200 µM L-glutamine, 10% FCS, penicillin (200 U/mL), and streptomycin (200 µg/mL). 21, 22 For cell cycle analysis, 1x10 6 cells were fixed in 70% ethanol and stained with propidium iodide (Roche Applied Science, Indianapolis, IN). Data were collected on a FACScalibur flow cytometer (BD Biosciences, San Jose, CA) using the CellQuest software and analyzed using ModFit LT software (Verity Software, Topsham, ME).
Western blot analysis, immunoprecipitation, and kinase assays
Whole cell lysates from Mo7ep210 BCR-ABL cells, cultured in the presence or absence of HEPES (pH 7.9), 50 mM KCl, 0.1 mM EDTA, 25% glycerol, 1 mM DTT, 1% protease inhibitor] for 30 mins. The nuclear extract was centrifuged at 95,000 rpm for 15 mins.
Nuclear proteins were precipitated with 3 M ammonium sulfate, pelleted by centrifugation at 50,000 rpm for 10 mins and resuspended in hypertonic buffer. Proteins (50-100 µ g) were resolved on SDS-PAGE. Antibodies used for immunoblotting were:
For personal use at PENN STATE UNIVERSITY on . bloodjournal.hematologylibrary.org From p27, cyclin E, CDK2, Jak2, Flt3 (Santa Cruz Biotechnology, Santa Cruz, CA); SKP2, CKS1 (Zymed, San Francisco, CA); pJak2, pFlt3, PDGFRβ (Cell Signaling, Danvers, MA); SP1 (Upstate, Charlottesville, VA) and α -tubulin (Sigma). KPC1/2 antibodies were generously provided by Dr. K. I. Nakayama (Kyushu University, Fukuoka, Japan).
Kinase assays were performed using histone H1 as a substrate.
23,24
Quantitative RT-PCR analysis RNA was extracted using RNeasy Mini Kit (QIAGEN, Valencia, CA 
Retroviral constructs and in vitro transformation assays
p210 BCR-ABL and control retroviruses were generated as described above. For titration of retrovirus, serial dilutions of each retroviral supernatant were used to infect NIH3T3 cells and after 48 hrs, the cells were analyzed for GFP expression by FACSaria. Volumes of supernatant containing equal number of infectious particles were used to infect bone marrow cells.
For myeloid progenitor colony formation assays, bone marrow was harvested from non-5-fluorouracil treated 6-10 week old mice, subjected to red cell lysis in NH 4 Cl solution (0.8% NH 4 Cl with 0.1 mM EDTA) and pre-stimulated at 37°C in IMDM with 15% FCS, 5% WEHI-3B, murine IL-3 (6 ng/ml), IL-6 (10 ng/ml), and SCF (50 ng/ml) 29 Cells were cultured for four weeks and fed twice weekly.
Cultures were scored as positive for transformation when the number of non-adherent cells exceeded 10 6 /ml of culture medium.
Bone marrow transplantation assay
Murine bone marrow transplantation was performed as previously described. 26, 30 To determine whether the number of target cells for transformation was comparable, marrow from 5-FU treated and untreated SKP2+/+ and SKP2-/-mice was immunophenotyped using PE-Cy7-conjugated CD3ε, B220, Gr-1, CD4, CD8a, , (WBC) and three-part differential blood counts were analyzed twice weekly using a Vet ABC blood analyzer (Heska Inc., Fort Collins, CO, USA). Diseased mice were subjected to histopathological analysis. Immunohistochemical analysis of spleen tissue for p27 was performed using anti-p27 antibody (C19; Santa Cruz Biotechnology). Southern blot analysis was performed as described earlier. 33 Bone marrow and spleen cells of each group were also analyzed by FACSaria using above described antibodies.
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Results
Inhibiting BCR-ABL kinase activity blocks cell cycle progression and up-regulates nuclear p27.
We examined the effect of BCR-ABL kinase inhibition on cell cycle kinetics in Mo7e cells expressing p210 p27 phosphorylated at T187 accumulates in the nucleus despite reduced CDK2 activity.
To determine the precise mechanism of imatinib-induced cell cycle arrest, we investigated the effect of BCR-ABL inhibition on the expression of Cyclin E and CDK2 and no differences were observed in imatinib-treated Mo7ep210 BCR-ABL cells ( Figure 1C , Panel 2, 3) . However, the kinase activity of anti-CDK2 immunoprecipitates from whole cell lysates was significantly reduced at 16 hrs (32±14.1%, p=0.001) ( Figure 1E ). As expected, ≥ 90% of CDK2 activity was nuclear, and a significant reduction was demonstrable at 16 hrs (31.4±13.7% of controls, p<0.001), while cytoplasmic kinase activity was barely detectable ( Figure 1E ). To assure that the activity of anti-CDK2
immunoprecipitates was indeed CDK2-specific, we treated anti-CDK2
immunoprecipitates with a CDK2 inhibitor and observed a dose-dependent reduction of activity (Suppl. figure 2 ).
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From p27 is phosphorylated by Cyclin E/CDK2 on threonine 187, generating a recognition site for SKP2, the F-box protein of the SCF SKP2 E3 ubiquitin ligase, which targets p27 for proteasomal degradation. Given the reduction in nuclear CDK2 activity, we hypothesized that T187 phosphorylation of p27 may be reduced. However, despite the reduced CDK2 kinase activity, most p27 was phosphorylated on T187 in imatinib-treated cells, but not in controls ( Figure 1C and Suppl. figure 3A , Panel 4) . No T187 phosphorylated p27 was detected in the cytoplasm ( Figure 1C , Panel 4), suggesting that p27 accumulation is due to impaired degradation and not to an inability to be recognized by SKP2.
Inhibition of BCR-ABL kinase leads to the down-regulation of SKP2.
Nuclear p27 phosphorylated on T187 is a target for the SCF SKP2 complex, while cytoplasmic p27 is degraded by KPC1/2 in a phosphorylation-independent manner. We Growth factor deprivation leads to the downregulation of SKP2.
In order to investigate the effect of GM-CSF signaling on p27 and SKP2 expression, 
SKP2 expression is regulated by oncogenic tyrosine kinases other than BCR-ABL.
To determine whether SKP2 is a universal target for oncogenic tyrosine kinases in leukemia, we treated various leukemia lines with specific pharmacological inhibitors.
MOLM14 cells express FLT3 with an internal tandem duplication, were treated with 500 After 24 hrs incubation the levels of p27 and SKP2 were determined by immunoblot analysis ( Figure 3C ). In analogy to BCR-ABL, inhibition of FLT3-ITD, JAK2 V617F and TEL-PDGFR was associated with reduced expression of SKP2 and accumulation of p27.
This suggests that the SKP2-p27 axis is commonly activated in leukemias driven by constitutively active tyrosine kinases.
In vitro transformation of primary bone marrow cells by BCR-ABL in SKP2+/+ vs.
SKP2-/-bone marrow.
To determine whether SKP2 is a crucial downstream target of BCR-ABL in primary hematopoietic cells, we tested the ability of BCR-ABL to transform cells in the absence of SKP2. Mice null for SKP2 are viable and fertile and have normal body proportions, although their size is reduced. 40 In preliminary experiments, we determined whether the distribution of immunophenotypically defined subsets of hematopoietic cells is altered in SKP2-/-bone marrow cells. 31, 41 No significant differences were observed in stem cells For To establish whether the defect in myeloid transformation observed in vitro would lead to decreased leukemogenicity in vivo, bone marrow from 5-FU treated SKP2+/+ and SKP2-/-mice was infected with BCR-ABL retrovirus and transplanted into lethally irradiated SKP2+/+ recipients. To control for a potential bias due to differences in the target cell populations, we immunophenotypically compared the bone marrow cells of 5- Figure 5B). Consistent with the more aggressive leukemia phenotype, white blood cell counts were higher in mice transplanted with SKP2+/+ marrow compared to mice transplanted with SKP2-/-marrow (median 59.1x10 3 /µl vs. median 7.9x10 3 /µl) and spleen weight was also significantly higher (0.42±0.07 g vs. 0.28± 0.09 g) ( Table 1) .
Southern blot analysis from spleen of leukemic SKP2+/+ and SKP2-/-mice suggests that disease is oligoclonal in both groups ( Figure 5C ). Histopathology revealed a CML-like MPD characterized by trilineage extramedullary hematopoiesis in the spleen and liver. In the lungs, infiltration of granulocytes in interstitial spaces resulted in the formation of focal hemorrhages ( Figure 6A ). Peripheral blood smears showed mainly mature neutrophils with few myeloid and erythroid precursors and some reticulocytes. Blasts were rare and when present did not account for greater than 3% of the WBC ( Figure 6B ).
The bone marrow was hypercellular, with maturing granulocytes and clusters of megakaryocytes, which were more pronounced in mice transplanted with SKP2+/+ cells. 
Discussion
The chronic phase of CML is characterized by expansion of the myeloid cell compartment with preserved terminal differentiation capacity. It is thought that reduced apoptosis and increased proliferation underlie this phenotype, which in many ways resembles the adenoma stage of solid tumors. In normal hematopoietic progenitor cells S phase entry is tightly regulated by exogenous cytokines, and consistent with this, normal CD34+ cells arrest in G0/G1 after cytokine withdrawal. 9 In contrast, a much larger fraction of CD34+ cells isolated from CML patients remains in S phase under the same conditions, suggesting that BCR-ABL kinase activity promotes cell cycle progression by mimicking cytokine stimulation. The effector molecules mediating this process are partially cell-type specific. For example, cyclin D2 expression is induced by BCR-ABL in B-lymphoblasts, but not myeloblasts. 42 In contrast, down-regulation of p27 appears to be a consistent effect of BCR-ABL kinase activity. One potential explanation is that the reduced p27 levels facilitate G1-S progression by relieving p27 inhibition of CDK2/CyclinE, the net result being increased cell proliferation. There is evidence that BCR-ABL regulates p27 through the PI3K pathway. PI3K signaling has been shown to only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From reduce p27 levels by two mechanisms. Firstly, PI3K activates AKT, which phosphorylates Forkhead/FoxO transcription factors, leading to reduced p27 transcription. 43 Secondly, PI3K induces transcription of SKP2, the F-box protein of the SCF SKP2 complex, which targets p27 for proteasomal degradation. 14 SKP2 is a bona fide oncogene, a notion based on the inverse correlation between SKP2 and p27 expression observed in many advanced solid tumors, 19 the poor prognosis of tumors with high SKP2 expression [15] [16] [17] [18] and in vitro cooperation between SKP2 and activated RAS in fibroblast transformation assays. 20 However, neither the ability of SKP2 to contribute to or induce reasoned that the accumulation of nuclear p27 may be due to reduced T187 phosphorylation as a result of reduced CDK2 activity. Additionally, it was recently shown that BCR-ABL phosphorylates tyrosine 88 of p27 when p27 is in complex with CDK2. This results in partial activation of CDK2, which then phosphorylates p27 on T187, promoting its ubiqitination by SCF SKP2 and subsequent degradation in the sense of a positive feedback loop. 44 However, using a pT187-specific antibody, we found a only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From marked increase of pT187p27, suggesting that p27 accumulation was caused by a block of degradation at the level of SCF SKP2 . Consistent with this hypothesis SKP2 levels decreased upon imatinib exposure ( Figure 1C ). In contrast, the levels of CKS1, another essential component of SCF SKP2 known to be upregulated in some types of cancer, [45] [46] [47] remained unchanged. As expected from the minimally altered levels of cytoplasmic p27, there was no change in the expression of KPC1/2, the ubiquitin ligase responsible for degradation of cytoplasmic p27. 48 The central role of SKP2 for the cell cycle dysregulation of BCR-ABL expressing cells was further supported by the fact that G0/G1 accumulation upon imatinib exposure was reduced in Ba/F3p210 BCR-ABL cells ectopically expressing wild type SKP2 ( Figure 2C,D) . Contrary to expectations, we observed an increase of cells in S phase upon expression of a SKP2 mutant (R294A) that is unable to recognize p27 for its ubiquitintion, albeit somewhat less than upon expression of the wild type construct. 34, 35 This suggests that SKP2 has cell cycle effects that are not impacted by the R294A mutation, for example through targeting proteins other than p27 for degradation. The identity of these substrates is currently unknown, since the levels of the known SCF SKP2 targets p130, p57 and Tob1 remained constant upon imatinib treatment of Mo7ep210 BCR-ABL and Ba/F3p210 BCR-ABL cells. In contrast to published work 14 no change of p21 levels was seen in Mo7ep210 BCR-ABL cells, and levels were decreased in Ba/F3p210 BCR-ABL cells, suggesting that p21 is not essential for the cell cycle block. The precise mechanism by which BCR-ABL regulates SKP2 remains to be established. In accord with a previous study 14 we found that SKP2 mRNA levels are reduced in suggesting that the SKP2/p27 axis may be a universal target of leukemogenic tyrosine kinases ( Figure 3C ).
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The importance of SKP2 for BCR-ABL-mediated leukemogenesis was confirmed by studies using bone marrow from SKP2-/-mice infected with BCR-ABL retrovirus.
Compared to wildtype marrow, formation of myeloid colonies by SKP2 null marrow in the presence and absence of cytokines was reduced by 28.3±4.7% and 50.4±3.4%, respectively. This difference is not caused by reduced numbers of target cells for transformation, as FACS analysis of bone marrow cells from SKP2-/-and SKP2+/+ cells revealed no significant differences in expression of stem/progenitor cell markers, with the exception of a slight increase in CD19+/B220+ B cells. In contrast to myeloid colony formation, no consistent differences were observed in B-cell transformation assays. In light of the limited capacity of this assay to quantify transformation potency, it is possible that the differences may have been too small to be detected. Alternatively, there could be a genuine difference in the requirement of SKP2 for the transformation of myeloid vs. lymphoid cells, which would not be unprecedented. For example, Gab-1 is essential for myeloid leukemogenesis but not B-cell leukemia, 52 while Src kinases may be required for B-cell transformation but not MPD. 53 The myeloid transformation defect of SKP2-/-marrow was confirmed in vivo. Mice transplanted with BCR-ABL-infected SKP2-/-marrow had lower white cell and platelet counts, smaller spleens and significantly increased survival compared to recipients of wildtype marrow ( Figure 5 , Table 1 ).
Standard histology was similar, apart from a markedly reduced reticulin fibrosis in recipients of SKP2-/-marrow. p27 levels were increased in leukemic SKP2-/-cells compared to wild type cells. In BCR-ABL expressing cells, more p27 seemed to localize to the cytoplasm ( Figure 6C , compare a with c and b with d), which is consistent with observations in human CD34+ CML cells. 10 However, a direct comparison is difficult only.
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In summary we provide evidence that SKP2 is required for full phenotypic penetrance of BCR-ABL-induced MPD. Since the structure of p27 bound to SKP2 and CKS1 has been solved, 34 it may be possible to design compounds that stabilize p27 by blocking its binding to the SCF SKP2 complex. Such compounds may be effective in treating leukemias caused by constitutively active tyrosine kinases. 
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